Nuclear lamin A inhibits adipocyte differentiation: implications for Dunnigan-type familial partial lipodystrophy

RL Boguslavsky, CL Stewart… - Human molecular …, 2006 - academic.oup.com
RL Boguslavsky, CL Stewart, HJ Worman
Human molecular genetics, 2006academic.oup.com
Mutations in the LMNA gene encoding A-type lamins cause several diseases, including
Emery–Dreifuss muscular dystrophy and Dunnigan-type familial partial lipodystrophy
(FPLD). We analyzed differentiation of 3T3-L1 preadipocytes to adipocytes in cells
overexpressing wild-type lamin A as well as lamin A with amino acid substitutions at position
482 that cause FPLD. We also examined adipogenic conversion of mouse embryonic
fibroblasts lacking A-type lamins. Overexpression of both wild-type and mutant lamin A …
Abstract
Mutations in the LMNA gene encoding A-type lamins cause several diseases, including Emery–Dreifuss muscular dystrophy and Dunnigan-type familial partial lipodystrophy (FPLD). We analyzed differentiation of 3T3-L1 preadipocytes to adipocytes in cells overexpressing wild-type lamin A as well as lamin A with amino acid substitutions at position 482 that cause FPLD. We also examined adipogenic conversion of mouse embryonic fibroblasts lacking A-type lamins. Overexpression of both wild-type and mutant lamin A inhibited lipid accumulation, triglyceride synthesis and expression of adipogenic markers. This was associated with inhibition of expression of peroxisome-proliferator-activated receptor gamma 2 (PPARγ2) and Glut4. In contrast, embryonic fibroblasts lacking A-type lamins accumulated more intracellular lipid and exhibited elevated de novo triglyceride synthesis compared with wild-type fibroblasts. They also had increased basal phosphorylation of AKT1, a mediator of insulin signaling. We conclude that A-type lamins act as inhibitors of adipocyte differentiation, possibly by affecting PPARγ2 and insulin signaling.
Oxford University Press